DRMA
Dermata Therapeutics, Inc.
$1.28
-0.02 (-1.54%)
At close · Jul 16
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed May 13, 2026
Market Cap
$5.15M
Shares
4,022,143
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.28
Open$1.28
Day$1.27–1.36
52W$1.10–7.50
Avg vol 30d83K
Short int131K · 3.3% float · 1.2d
Short vol29%
Last earningsNov 15, 2021
DataAug 2021–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
+1%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
3%
near low
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−47%
trailing
YTD return
−45%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 7 funds reported for Jun 30 · net +26 sh shares · +1 new
Insider flow
Distributing
Net -$13 over 90 days · 100% sells
Short interest
Rising
3.27% of float · ▲ +41.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
7 holders — 13F breadth
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
+90%
Y/Y
Balance sheet
$7.5M
net cash
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 7 funds reported for Jun 30 · net +26 sh shares · +1 new
Insider flow
Distributing
Net -$13 over 90 days · 100% sells
Short interest
Rising
3.27% of float · ▲ +41.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
7 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $1 · 3%
52-wk high $8
vs 200-day avg -38%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DRMA
this stock
Dermata Therapeutics, Inc.
|
$5.15M | -44.8% | — | — | 3.3% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DRMA | -4.5% | +7.6% | -46.9% | -0.8% | -44.8% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -4.4% | +7.5% | -55.9% | -1.3% | -54.9% |